SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-200260"
 

Search: onr:"swepub:oai:DiVA.org:liu-200260" > Injectable Biodegra...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Mcgowan, AsmaaDelSiTech Ltd, Finland (author)

Injectable Biodegradable Silica Depot for Controlled Subcutaneous Delivery of Antisense Oligonucleotides with beyond Monthly Administration

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • AMER CHEMICAL SOC,2023
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-200260
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-200260URI
  • https://doi.org/10.1021/acs.molpharmaceut.3c00663DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Single-stranded antisense oligonucleotides (ASOs) are typically administered subcutaneously once per week or monthly. Less frequent dosing would have strong potential to improve patient convenience and increase adherence and thereby for some diseases result in more optimal therapeutic outcomes. Several technologies are available to provide sustained drug release via subcutaneous (SC) administration. ASOs have a high aqueous solubility and require relatively high doses, which limits the options available substantially. In the present work, we show that an innovative biodegradable, nonporous silica-based matrix provides zero-order release in vivo (rats) for at least 4 weeks for compositions with ASO loads of up to about 100 mg/mL (0.5 mL injection) without any sign of initial burst. This implies that administration beyond once monthly can be feasible. For higher drug loads, substantial burst release was observed during the first week. The concentrations of unconjugated ASO levels in the liver were found to be comparable to corresponding bolus doses. Additionally, infusion using a minipump shows a higher liver exposure than SC bolus administration at the same dose level and, in addition, clear mRNA knockdown and circulating protein reduction comparable to SC bolus dosing, hence suggesting productive liver uptake for a slow-release administration.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Gennemark, PeterLinköpings universitet,Avdelningen för medicinsk teknik,Tekniska fakulteten,AstraZeneca, Sweden(Swepub:liu)petge96 (author)
  • Akieh-Pirkanniemi, MarcelineDelSiTech Ltd, Finland (author)
  • Wirman, LindaDelSiTech Ltd, Finland (author)
  • Davies, NigelAstraZeneca, Sweden (author)
  • Elebring, MarieAstraZeneca, Sweden (author)
  • Tivesten, AnnaAstraZeneca, Sweden (author)
  • Strimfors, MarieAstraZeneca, Sweden (author)
  • Holtta, MikkoAstraZeneca, Sweden (author)
  • Soderberg, MagnusAstraZeneca, Sweden (author)
  • Berntsson, VeronicaAstraZeneca, Sweden (author)
  • Balas, DanielaAstraZeneca, Sweden (author)
  • Koskinen, MikaDelSiTech Ltd, Finland (author)
  • Leino, LasseDelSiTech Ltd, Finland (author)
  • Abrahmsen-Alami, SusannaAstraZeneca, Sweden (author)
  • DelSiTech Ltd, FinlandAvdelningen för medicinsk teknik (creator_code:org_t)

Related titles

  • In:Molecular Pharmaceutics: AMER CHEMICAL SOC21:1, s. 143-1511543-83841543-8392

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view